Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

Sanofi is paying $129 per share in cash for Blueprint, amounting to a $9.1 billion equity value and a 27% premium on the biotech’s closing price on Friday.

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

PHOENIX – A long-time leader in iron innovation and performance, today PING introduced the Blueprint S and Blueprint T, two new forged iron models engineered and custom-built for golfers seeking ...

The Blueprint became law in 2021 after the General Assembly overrode a veto of the bill by former Gov. Larry Hogan. The Kirwan Commission was formed in 2016 and worked for three years to develop ...

Blueprint was prepared to spend $5,537,927 on the redesign. It is unclear where these funds will be shifted to now. The agency is still eager to work something out with FDOT if possible, but the ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...

The two companies said on Monday that Sanofi would initially pay $129.00 per share in cash, or around $9.1 billion. Blueprint shares jumped 27% to $128.74 in premarket trade.